Comparative Effects of Desloratadine versus Montelukast on Asthma Symptoms and Use of β<sub>2</sub>-Agonists in Patients with Seasonal Allergic Rhinitis and Asthma

Abstract

Asthma symptoms and beta(2)-agonist were improved significantly in patients with concomitant SAR and asthma treated with desloratadine 5 mg as well as montelukast 10 mg once daily. Both therapies significantly improved FEV(1) in a subset of patients with FEV(1) <80% of predicted normal at entry. Improvements in asthma symptoms were comparable for both active treatment groups.